Bortezomib (NF-κB inhibitor) and docetaxel (PI3K/AKT inhibitor) demonstrated significant correlations with index I, indicating that ROS accumulation may abrogate the anti-tumor effects of these drugs. This evidence concerns the gene NFKB1 and neoplasm.